On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial

Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study

A Noninvasive Multianalytical Approach for Lung Cancer Diagnosis of Patients with Pulmonary Nodules

Short-term Response to Immune-chemotherapy and Immune Features of a Ceritinib-resistant Patient with ROS1-rearranged Lung Adenocarcinoma

Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers

Massive PD-L1 and CD8 double positive Tils characterize an immunosuppressive microenvironment with high mutational burden in lung cancer

Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective,single-arm, phase II study (TD-NICE)

Perioperative ctDNA-based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1)

Characterization of Hyperprogression after Immunotherapy in a Lung Adenocarcinoma Patient with Strong Expression of PD-L1

Genomic and Immune Features in an Intrahepatic Cholangiocarcinoma Patient with Microsatellite Instability-High Suffered Rapid Acquired Resistance to PD-1 Inhibito

HLA-I evolutionary divergence confers response to PD-1 blockade plus chemotherapy in untreated advanced non-small-cell lung cancer

Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer

Clinical Outcome and Molecular Analysis of a Chinese Patient With Lung Adenocarcinoma Harboring Rare EGFR Mutation V834L

Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker

Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy

Intraperitoneal and Intravenous Paclitaxel plus S-1 and Sintilimab as First-line Treatment for Gastric Cancer with Peritoneal Metastasis: A Single-arm Phase 2 Trial (DRAGON-09)

MEK inhibitors for the treatment of immunotherapy-resistant, AGK-BRAF fusion advanced acral melanoma: A case report and literature review

Analysis of actionable gene fusions in a large cohort of Chinese patients with colorectal cancer

Rare SMARCA4-Deficient Thoracic Tumor: Insights into Molecular Characterization and Optimal Therapeutics Methods

Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment

Identification of gene variation feature for targeted therapy of non-small cell lung cancer through combined method of DNA and RNA sequencing

Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study

A Systematic Method to Detect Next-Generation Sequencing-Based Microsatellite Instability in Plasma Cell-Free DNA: plasmaMSI

Chemotherapy combined with immunotherapy in a patient with multiple primary gastric and rectal cancers with good prognosis: a case report

Genomic correlates of the response to first-line PD-1 blockade plus chemotherapy in patients with advanced non-small-cell lung cancer

Chronic obstructive pulmonary disease alters the genetic landscape and tumor immune microenvironment in lung cancer patients

TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis

Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials

EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma